Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Phase II Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Sponsor: University of Chicago
Terminated
side effects (rash)
Other terminated trials from University of Chicago
A PHASE2 clinical study on Breast Cancer and Triple Negative Breast Neoplasms, this trial is terminated or withdrawn. The trial is conducted by University of Chicago and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Nov 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
May 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2021 — May 2023 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Nov 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Nov 2019 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .